Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature

Table 3 Patients’ allocation and their median survival according to prognostic scores taken into account

Score	Number of patients	Percentage	Median survival in mo	Statistical significance for prognostic stratification	Median survival in the original study in mo
ITA.LI.CA				P < 0.001
0	7	5%	93.5
1	33	23.6%	57.9
2	19	13.6%	63.1
3	38	27.1%	40.6
4	20	14.3%	25.2
5	11	7.8%	21.1
6	5	3.6%	20.8
7	4	2.9%	10.3
8	3	2.1%	4.3
> 8	0	0%
ITA.LI.CA
0-1	40	28.6%	57.9		57-61
2-3	57	40.7%	43		43-48
4-5	31	22.1%	21.7		23
> 5	12	8.6%	10.4		9-8
BCLC				P = 0.001
0	15	10.7%	> 81.1		> 60
A	83	59.3%	44.9		> 60
B	38	27.1%	21.3		20
C	2	1.4%	3.1		11
D	0	0%			< 3
BCLC A				P = 0.022
A1	29	20.7%	61.9		43.4
A2	25	17.6%	44.3		28.9
A3	5	3.5%	10.7		25.4
A4	24	17.1%	34.4		22.3
BCLC B (Bolondi)				P = 0.007
B1	13	9.3%	34.7		31.9
B2	19	15.7%	25.2		26.9
B3	3	0.7%	10.4		13.5
B4	3	1.4%	7.8		10.9
CLIP				P = 0.001	32
0	59	42.1%	50.7		27
1	47	33.6%	53.3		15
2	19	13.6%	20.5		9
3	12	8.6%	17.8		7
4	3	2.1%	3.1		5
> 4	0	0%			3
JIS				P = 0.049
0	27	19.3%	70.8		22.6
1	66	47.1%	44.3		22
2	40	28.6%	42		20.6
3	7	5%	10.4		16.9
4-5	0	0%			12.1-5.9
HKLC				P < 0.001
1	93	67.4%	47		79.7
2a	10	7.3%	19		33.4
2b	18	13%	34.7		32.7
3a	5	3.6%	10.4		12.5
3b	10	7.3%	20.8		5.5
4a	1	0.7%	17.8		3.9
4b	1	0.7%	3.1		1.9
5 (a/b)	0	0%			32.5/1.6
Tokyo				P = 0.002
0	10	7.1%	93.5
1	48	34.3%	47
2	41	29.3%	43.6
3	21	15%	30.3
4	14	10%	20.8
5	4	2.9%	10.4
6	1	0.7%	10.3
7	0	0%
8	1	0.7%	0.8
Okuda				P = 0.026
1	102	72.9%	45.5		15.8
2	36	25.7%	20.5		3.6
3	2	1.4%	0.8		1.3
GRETCH				P < 0.001
A	75	53.6 %	57.6		29.3
B	62	44.3 %	30		7.4
C	3	2.1 %	7.8		2.1
NIACE				P = 0.001
0	77	55 %	45.7		44
1	10	7.1 %	43		22
1.5	39	27.9 %	21.7		20
2.5	5	3.6 %	10.4		14
3	6	4.3 %	16.5		9
4	3	2.1 %	3.1		7
> 4	0	0 %			4
MESH				P < 0.001
0	40	28.6 %	57.9		66
1	46	32.9 %	43		37
2	30	21.4 %	19.5		21
3	19	13.6 %	20.8		10
4	5	3.5 %	10.4		5
> 4	0	0 %			4
ALBI				P = 0.008
1	43	31.9 %	79.2		24.7
2	87	64.4 %	34.7		11.4
3	5	3.7 %	15.7		4.9
ALBI				P = 0.008
2a	53	39.2 %	44.3		14.5
2b	34	25.2 %	25.2		6.6
BCLC based on ALBI				P = 0.048
0	15	10.9 %	> 81.1
A	75	54.3 %	44.9
B	20	14.5 %	22.2
C	1	0.7 %	3.1
D	27	19.6 %	21.7
ALBI-T				P = 0.002
0	12	9 %	93.5		137.7
1	42	31.6 %	63.1		83.2
2	49	36.8 %	42		53.4
3	28	21.1 %	21.3		27.4
4	2	1.5 %	0.8		5
5	0	0 %			1.4
HAP				P = 0.004
A	31	22.2 %	45.7		25.5
B	51	36.4 %	45.7		18.1
C	41	29.3 %	35.7		8.9
D	17	12.1 %	20.6		5.9
STATE				P = 0.322	20.5 (≥ 18 points)
> 37	8	5.7 %	25.2
27-37	17	12.1 %	40.6
18-27	16	11.4 %	44.9
< 18	13	9.3 %	20
Median STATE score	29.1 (range: 2.4 – 45.6)				6.1
SNACOR				P = 0.09
0-2	31	22.1 %	25.2		31.5
3-6	17	12.1 %	19		19.9
7-10	1	0.7 %	10.3		9.2
NSP				P = 0.03
0	63	45 %	79.2
1	49	35 %	42
2	11	7.9 %	14.9
3	10	7.1 %	20
4	4	2.9 %	22.2
5	3	2.1 %	5.6
NSP				P = 0.002
0-1	13	9.3 %	47		51.5
> 1	25	17.9 %	20.5		17.3

Comparison with data in original studies which available. NS: Not significant. ALBI: Albumin-bilirubin; BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program; GRETCH: Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire; HAP: Hepatoma arterial embolization; HKLC: Hong Kong Liver Cancer; ITA.LI.CA: Italian Liver Cancer; JIS: Japanese Integrated Staging; MESH: Model to estimate survival for hepatocellular carcinoma patients; NSP: Needle and syringe programme; SNACOR: Tumor size and number, baseline alpha-fetoprotein, Child-Pugh and objective radiological response; STATE: Selection for Transarterial chemoembolization treatment.